Real-world treatment patterns and outcomes in patients with chronic lymphocytic leukemia previously exposed to both covalent Bruton's tyrosine kinase inhibitor and B-cell lymphoma 2 inhibitor therapy
Authors
Enrico De Nigris
Jennifer Prescott (ORCID: https://orcid.org/0000-0002-5703-8953)
Paul M. Barr (ORCID: https://orcid.org/0000-0002-9733-401X)
Matthew Steven Davids (ORCID: https://orcid.org/0000-0003-4529-2003)
Christina M. Zettler (ORCID: https://orcid.org/0000-0002-7516-593X)
Laura L. Fernandes (ORCID: https://orcid.org/0000-0002-5986-3885)
Jacob P. Ambrose (ORCID: https://orcid.org/0000-0001-7157-0834)
Siyang Leng (ORCID: https://orcid.org/0000-0002-4852-7114)
Ching-Kun Wang
Jing Yang
Institutions
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Real-world treatment patterns and outcomes in patients with chronic lymphocytic leukemia previously exposed to both covalent Bruton's tyrosine kinase inhibitor and B-cell lymphoma 2 inhibitor therapy
Enrico De Nigris, Jennifer Prescott, Paul M. Barr, Matthew Steven Davids et al.
Journal
Haematologica
Topics
Chronic Lymphocytic Leukemia Research
article
Real-world treatment patterns and outcomes in patients with chronic lymphocytic leukemia previously exposed to both covalent Bruton's tyrosine kinase inhibitor and B-cell lymphoma 2 inhibitor therapy
Enrico De Nigris, Jennifer Prescott, Paul M. Barr, Matthew Steven Davids, Christina M. Zettler, Laura L. Fernandes, Jacob P. Ambrose, Siyang Leng, Ching-Kun Wang, Jing Yang
article en
Abstract
No abstract available for this paper.
Publication Tag
Haematologica
Institutions
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), MSD (UK) Limited (United Kingdom) (GB), Dana-Farber Cancer Institute (US), University of Rochester (US)